Vision for Life — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$22,000	10
2022	Research	$19,038	3
2021	Research	$31,078	7
2019	Research	$74,358	8

Breakdown

Who paid Research payments · program years 2019–2023

Novartis Pharmaceuticals Corporation $68,501 4 payments
Alcon Research LLC $48,479 20 payments
Bausch & Lomb Americas Inc. $29,494 4 payments

Studies the money was for Research payments · program years 2019–2023

Phase II Study Unr844 1.5% in Subjects With Presbyopia $46,582 1 payment
A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the Envista One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction $29,494 4 payments
Post Approval Study of the AcrySof IQ ReSTOR Toric IOL (Models SND1T3-T6) $23,276 2 payments
A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $19,903 2 payments
Post Approval Study of the AcrySof IQ ReSTOR Toric IOL $14,304 5 payments
Long-term evaluation of safety and performance of Clareon Presbyopia-Correction IOLs PMCF Study of Clareon Vivity and Clareon PanOptix $6,400 8 payments
Postmarket Study of ORA with VerifEye Plus and Barrett Toric Algorithm used for the implantation of Acrysof Toric(Alliances - Project Calgary) $4,500 5 payments
A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $2,016 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.